Herbert Smith Freehills Kramer advises PYC Therapeutics Limited on ~A$653 million capital raise

Herbert Smith Freehills Kramer (HSF Kramer) is proud to have advised PYC Therapeutics Limited (ASX:PYC) (PYC) on its current capital raising to raise up to approximately A$653 million, comprising a placement of A$128 million to leading US specialist life sciences investors and an accelerated non-renounceable entitlement offer of up to A$525 million.

Upon successful completion of the capital raising, PYC will be funded into CY2030 with clinical trial progress and important near-term human efficacy data expected in all four of its drug development programs.